Alpha -Tocopherol Ascorbic Acid Aspirin Salix Alba
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Ascorbic Acid Aspirin Salix Alba
- Alpha-Tocopherol / Ascorbic Acid / Aspirin / Salix Alba Bark / Vitamin A: No TxGNN Repurposing Prediction Available
Alpha-Tocopherol / Ascorbic Acid / Aspirin / Salix Alba Bark / Vitamin A: No TxGNN Repurposing Prediction Available
One-Sentence Summary
This is a five-component combination product containing Vitamin E (alpha-tocopherol), Vitamin C (ascorbic acid), Aspirin, White Willow Bark (Salix alba bark), and Vitamin A — an antioxidant and anti-inflammatory blend with no approved indication on record in the queried regulatory database. The TxGNN model did not generate any repurposing predictions for this combination, as the product lacks a DrugBank ID required for knowledge-graph mapping. Without a model prediction or supporting evidence, this candidate cannot proceed to formal evaluation at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory record found) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; no supporting studies |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN model requires a valid DrugBank ID to anchor a drug to the biomedical knowledge graph. This submission is a multi-ingredient combination with no unified DrugBank entry, so the model pipeline could not produce a prediction.
Each individual ingredient does have an established mechanistic profile:
| Ingredient | Known Role | Individual DrugBank ID |
|---|---|---|
| Aspirin (Acetylsalicylic acid) | COX-1/COX-2 inhibitor — anti-inflammatory, analgesic, antiplatelet | DB00945 |
| Alpha-Tocopherol (Vitamin E) | Fat-soluble antioxidant; protects cell membranes from lipid peroxidation | DB00163 |
| Ascorbic Acid (Vitamin C) | Water-soluble antioxidant; supports collagen synthesis and immune defence | DB00126 |
| Salix Alba Bark (White Willow) | Salicin-containing botanical; metabolised to salicylate — anti-inflammatory | DB13156 |
| Vitamin A (Retinol) | Regulates cell differentiation, vision, and innate immune function | DB00162 |
Together, the combination presents a dual-pathway profile — antioxidant (Vitamins A, C, E) + salicylate-based anti-inflammatory (Aspirin + Salix alba) — but without a unified identifier and without a documented original indication, the TxGNN pipeline has no entry point to generate predictions.
A potential concern specific to this combination: Aspirin and Salix alba bark are both salicylate sources, raising the question of whether the formulation inadvertently duplicates pharmacological activity and increases salicylate exposure.
Safety Considerations
No structured safety data (warnings or contraindications) was retrieved for this combination as a unified product. The following notes are derived from the known profiles of the individual components:
- Dual salicylate burden: The co-presence of Aspirin and Salix alba bark means two independent salicylate sources. This may increase the risk of salicylate toxicity, gastrointestinal irritation, and bleeding — particularly relevant in elderly patients or those already on anticoagulant therapy.
- Potential drug interactions: Aspirin interacts with warfarin, other NSAIDs, SSRIs, and methotrexate. A combined product amplifies these risks without being formally tracked under a single drug entry.
- Fat-soluble vitamin accumulation: Alpha-tocopherol and Vitamin A are both fat-soluble; chronic high-dose use carries a risk of hypervitaminosis A (teratogenicity, hepatotoxicity) and, at very high Vitamin E doses, paradoxical pro-oxidant or anticoagulant effects.
Please refer to the package inserts of each individual ingredient for full safety information until a unified monograph is available.
Conclusion and Next Steps
Decision: Hold
Rationale: This combination product cannot be evaluated by the TxGNN pipeline in its current form — it lacks a DrugBank ID, approved indication, and model predictions. The regulatory record is empty and safety data is unavailable. Proceeding without these inputs would produce an assessment without evidentiary foundation.
To proceed, the following is needed:
- Decompose and re-run individually: Submit each of the five ingredients separately through the TxGNN pipeline using their individual DrugBank IDs (DB00945, DB00163, DB00126, DB13156, DB00162), then aggregate and compare predicted indications for mechanistic overlap.
- Clarify product intent: Determine the intended therapeutic or preventive use of this specific combination — i.e., why these five ingredients are co-formulated. This drives the “original indication” anchor for repurposing analysis.
- Obtain safety documentation: Download and parse the package insert (if any exists) or equivalent product monograph to populate warnings and contraindications.
- Verify salicylate dosing: Quantify the total salicylate contribution from both Aspirin and Salix alba bark to assess duplication risk before any clinical evaluation.
- Resolve regulatory status: Confirm whether this combination holds an authorisation in any jurisdiction (EU, US, Japan, etc.) — the Taiwan query returned zero results but a DrugBank query returned one result, suggesting partial data may exist.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.